[go: up one dir, main page]

PE109599A1 - Formas de dosificacion farmaceuticas solidas - Google Patents

Formas de dosificacion farmaceuticas solidas

Info

Publication number
PE109599A1
PE109599A1 PE1998000752A PE00075298A PE109599A1 PE 109599 A1 PE109599 A1 PE 109599A1 PE 1998000752 A PE1998000752 A PE 1998000752A PE 00075298 A PE00075298 A PE 00075298A PE 109599 A1 PE109599 A1 PE 109599A1
Authority
PE
Peru
Prior art keywords
pharmaceutical dosage
dosage forms
solid pharmaceutical
soluble
water
Prior art date
Application number
PE1998000752A
Other languages
English (en)
Inventor
Isaac Ghebre-Sellassie
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE109599A1 publication Critical patent/PE109599A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE REFRIERE A UNA FORMA DE DOSIFICACION FARMACEUTICA EN PARTICULAS SOLIDAS ADECUADAS PARA SUMINISTRO ORAL QUE COMPRENDE UN AGENTE FARMACEUTICO, COMO LA GLITAZONA, EN PARTICULAS, POBREMENTE SOLUBLE EN AGUA DISPERSADO EN UNA MATRIZ COMPUESTA POR UN POLIMERO SOLUBLE EN AGUA, EL CUAL PUEDE SER HIDROXIPROPIL CELULOSA; HIDROXIPROPIL METILCELULOSA Y POLIVINILPIRROLIDONA
PE1998000752A 1997-08-21 1998-08-20 Formas de dosificacion farmaceuticas solidas PE109599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5619597P 1997-08-21 1997-08-21

Publications (1)

Publication Number Publication Date
PE109599A1 true PE109599A1 (es) 1999-12-19

Family

ID=22002810

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000752A PE109599A1 (es) 1997-08-21 1998-08-20 Formas de dosificacion farmaceuticas solidas

Country Status (17)

Country Link
US (1) US20010048946A1 (es)
EP (1) EP1011640A1 (es)
JP (1) JP2001515029A (es)
KR (1) KR20010023085A (es)
AR (1) AR018252A1 (es)
AU (1) AU8600098A (es)
BR (1) BR9811972A (es)
CA (1) CA2292586C (es)
CO (1) CO4960652A1 (es)
GT (1) GT199800136A (es)
HN (1) HN1998000115A (es)
NZ (1) NZ502869A (es)
PA (1) PA8458101A1 (es)
PE (1) PE109599A1 (es)
SV (1) SV1998000104A (es)
WO (1) WO1999008660A1 (es)
ZA (1) ZA987551B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2527107B2 (ja) * 1991-04-16 1996-08-21 日本新薬株式会社 固体分散体の製造方法
WO1993003215A1 (en) * 1991-08-02 1993-02-18 Wilcom Tufting Pty. Ltd. A method and system of tufting
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
TR200201617T2 (tr) 1999-12-23 2002-10-21 Pfizer Products Inc. Kuvvetlendirilmiş ilaç konsantrasyonları sağlayan farmasötik kompozisyonlar
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20040013736A1 (en) * 2000-09-25 2004-01-22 Tomio Nakano Process for producing medicinal solid dispersion
DE60110192T2 (de) * 2000-12-07 2006-03-09 Warner-Lambert Company Llc Verfahren und System zur gleichmäßigen Arzneistoffabgabe
CA2450957A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
BR0307344A (pt) 2002-02-01 2004-12-14 Pfizer Prod Inc Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
AU2003249474A1 (en) * 2002-08-12 2004-02-25 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
US8273371B2 (en) * 2003-06-27 2012-09-25 Johan Adriaan Martens Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06000529A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para elaborarlas y utilizarlas.
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
PL1691787T3 (pl) * 2003-12-04 2008-11-28 Pfizer Prod Inc Sposób wytwarzania farmaceutycznych systemów wielocząstkowych
US20050249806A1 (en) * 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US9504658B2 (en) * 2004-11-09 2016-11-29 Board Of Regents, The University Of Texas System Stabilized HME composition with small drug particles
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
RU2412687C2 (ru) * 2004-12-30 2011-02-27 Пьер Фабр Медикаман Стабильная твердая дисперсия производного винка-алкалоида и способ ее получения
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
FR2880274B1 (fr) * 2004-12-30 2007-04-13 Pierre Fabre Medicament Sa Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication
EP1881819A1 (en) * 2005-05-10 2008-01-30 Novartis AG Extrusion process for making compositions with poorly compressible therapeutic compounds
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
AU2007335191A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical compound and composition
KR20110031485A (ko) * 2008-07-03 2011-03-28 노파르티스 아게 용융 과립화 방법
WO2010136604A1 (en) * 2009-05-29 2010-12-02 Dsm Ip Assets B.V. Transfer matrix for transferring a bioactive agent to body tissue
WO2012110469A1 (en) 2011-02-17 2012-08-23 F. Hoffmann-La Roche Ag A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
CN105142615A (zh) * 2011-09-14 2015-12-09 细胞基因公司 环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的制剂细胞基因公司公司设立的州：特拉华州

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPH054919A (ja) * 1990-07-25 1993-01-14 Sankyo Co Ltd チアゾリジン誘導体の固体分散体
JP2527107B2 (ja) * 1991-04-16 1996-08-21 日本新薬株式会社 固体分散体の製造方法
DE69222182T2 (de) * 1991-12-18 1998-02-26 Warner Lambert Co Verfahren für die herstellung einer festen dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
JPH07324086A (ja) * 1994-05-31 1995-12-12 Sankyo Co Ltd チアゾリジン誘導体の固体分散体または固体分散体製剤
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
PA8458101A1 (es) 2001-12-14
JP2001515029A (ja) 2001-09-18
AR018252A1 (es) 2001-11-14
CA2292586A1 (en) 1999-02-25
CO4960652A1 (es) 2000-09-25
WO1999008660A1 (en) 1999-02-25
BR9811972A (pt) 2000-08-15
ZA987551B (en) 1999-02-23
SV1998000104A (es) 1999-07-02
CA2292586C (en) 2006-02-14
NZ502869A (en) 2002-10-25
KR20010023085A (ko) 2001-03-26
HN1998000115A (es) 1999-06-02
AU8600098A (en) 1999-03-08
GT199800136A (es) 2000-02-11
US20010048946A1 (en) 2001-12-06
EP1011640A1 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
PE109599A1 (es) Formas de dosificacion farmaceuticas solidas
CO5611097A2 (es) Tableta farmaceutica
AR027065A1 (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
NO20004617L (no) Tablett som disintegrerer hurtig i munnhulen
CU23440B7 (es) Composición de liberación sostenida de pramipexol
UY28304A1 (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad
AR046811A1 (es) Formas de dosificacion oral de ziprasidona de liberacion sostenida
ATE253894T1 (de) Pharmazeutische suspensionssysteme
ATE251449T1 (de) Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
ATE381926T2 (de) Vitaminzusammenstellung mit verzögerter freigabe
ATE314054T1 (de) Osmotisches verabreichungssystem für lösliche dosen
JP2001515029A5 (es)
ES2183750T1 (es) Composicion nutritiva.
ATE372765T1 (de) Feste pharmazeutische formulierungen mit telmisartan
UY28281A1 (es) Productos farmacéuticos
WO2004110492A3 (en) Composition comprising triptans and nsaids
DE69832816D1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
DK1348429T3 (da) Smelteekstruderede opioidformuleringer, der kan administreres oralt
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
AU2003238221A1 (en) Ibuprofen suspension
BR0112847A (pt) Uso de uma forma de dosagem sólida
DE69928815D1 (de) Dosierungsform mit flüssiger formulierung
EP1221926A4 (en) PHARMACEUTICAL COMPOSITIONS WITH POOR SOLVENT MEDICAMENTS
DE69927374D1 (de) Entzündungshemmende pharmazeutische formulierungen
ECSP034451A (es) Composicion de eletriptan en forma de particulas

Legal Events

Date Code Title Description
FC Refusal